Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2212)	2/12/2008 1:18:06 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

LJPC has been up 12.07% & still is up 10.46% with volume of 37,456 about half its ADV bigcharts.marketwatch.com It announced yesterday progress in its PIII of Riquent, its drug candidate for SLE. So far, 607 patients have been enrolled of the targeted total of 740 patients & 2 safety reviews have shown no safety concerns with the the data continue to indicate that the 300 mg and 900 mg doses are as well tolerated as the 100 mg dose. The first interim efficacy analysis is expected in the 2ndQ & another in the 4thQ. Riquent has received an Approvable Letter, Fast Track status & Orphan Drug designation from the FDA LJP is expected to continue its long history of losses, with the EL for 2007 around $1.36 & the one 1n 2008 around the same range.(Both are somewhat better than previous estimates, but still > the $1.21 in 2006) The insiders reportedly hold > 20% & institutions >10% The short ratio came down about 40% but is still around 7x its ADV The "analysts" have a target around $6.33 which would be almost a 100% gain from present levels, but below its May H of $7.06 bigcharts.marketwatch.com Bernard